Skip to main content

Immunocore Holdings plc

IMCR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001671927

No open-market purchases or sales by Immunocore Holdings plc insiders were filed in the last 90 days; 135 institutions reported holding it in 13F filings for Q2 2026, worth $1.65B in total; no superinvestor holds it.

Q2 2022 vs. Q1 2022

How the institutions holding Immunocore Holdings plc changed between Q1 2022 and Q2 2022.

All holders in Q2 2022All holders in Q1 2022

13F holders of IMCR: Q1 2022 compared with Q2 2022
MeasureQ1 2022Q2 2022Change
Holders5766+9
Shares19.7M21.0M+1.30M (+6.6%)
Value$590.1M$784.5M+$194.4M (+32.9%)

New holders (14)

Institutions that held Immunocore Holdings plc at the end of Q2 2022 but not at the end of Q1 2022.

Institutions new to IMCR in Q2 2022
InstitutionSharesValue% of portfolio
CWM, LLC73,036$2.73M0.02%
UBS Oconnor LLC57,497$2.15M0.02%
Susquehanna International Group, LLP57,409$2.14M0.00%
Jane Street Group, LLC48,464$1.81M0.00%
Schonfeld Strategic Advisors LLC25,200$940.0K0.01%
Millennium Management LLC19,178$716.0K0.00%
LMR Partners LLP15,000$560.0K0.01%
Jump Financial, LLC13,200$492.0K0.02%
JPMorgan Chase & Co13,106$489.0K0.00%
State Street Corp11,834$442.0K0.00%
Dalton Investments LLC10,000$373.0K0.34%
Parallax Volatility Advisers, L.P.8,556$319.0K0.00%
Pura Vida Investments, LLC6,419$239.0K0.04%
Tower Research Capital LLC (TRC)285$11.0K0.00%

Sold out (5)

Institutions that held Immunocore Holdings plc at the end of Q1 2022 and filed for Q2 2022 without it.

Institutions that sold out of IMCR in Q2 2022
InstitutionShares, Q1 2022Value, Q1 2022
Point72 Asset Management, L.P.407,058$12.2M
Samlyn Capital, LLC380,811$11.4M
Artal Group S.A.200,000$5.98M
DAFNA Capital Management LLC53,878$1.61M
Balyasny Asset Management LLC52,174$1.56M